Nasal continuous positive airway pressure versus nasal intermittent positive-pressure ventilation within the minimally invasive surfactant therapy approach in preterm infants: a randomised controlled trial
- 9 November 2015
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 101 (4) , F323-F328
Abstract
Objective To compare the effectiveness of nasal continuous positive airway pressure (NCPAP) and nasal intermittent positive-pressure ventilation (NIPPV) as the initial respiratory support within the minimally invasive surfactant therapy (MIST) approach in preterm infants with respiratory distress syndrome. Design Prospective, randomised controlled study. Setting Tertiary neonatal intensive care unit. Patients and interventions This study enrolled 200 preterm infants with a gestational age of 26–32 weeks who showed signs of respiratory distress but did not require intubation in the delivery room. Surfactant therapy was performed using the MIST approach in the patients who met the criteria for surfactant administration. Main outcome measures The primary outcomes were a need for intubation within the first 72 h of life and a surfactant requirement. Results The infants in the study displayed similar characteristics at birth. Fewer infants in the NIPPV group required surfactant therapy (38% vs 60%; p=0.002) or invasive ventilation during the first 72 h of life (13% vs 29%; p=0.005), and NIPPV reduced the rate of moderate-to-severe bronchopulmonary dysplasia (BPD) (7% vs 16%; p=0.046). Multivariate logistic regression analysis showed that NIPPV support (OR: 0.36, 95% CI 0.17 to 0.76; p=0.008) and higher gestational age (OR: 0.76, 95% CI 0.59 to 0.98; p=0.041) reduced the need for invasive ventilation within the first 72 h of life. Surfactant requirement was also decreased with NIPPV support (OR: 0.39, 95% CI 0.22 to 0.71; p=0.002). However, there was no impact on BPD, based on the multivariate analysis. Conclusions In infants born at 26–32 weeks’ gestation, NIPPV reduced the need for invasive ventilation and the surfactant requirement within the MIST approach. Trial registration number ClinicalTrials.gov under identifier NCT01741129.Keywords
This publication has 30 references indexed in Scilit:
- Noninvasive Ventilation for Respiratory Distress Syndrome: A Randomized Controlled TrialPediatrics, 2011
- Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research NetworkPediatrics, 2010
- Early nasal intermittent positive pressure ventilation versus continuous positive airway pressure for respiratory distress syndromeActa Paediatrica, 2009
- Very Early Surfactant Without Mandatory Ventilation in Premature Infants Treated With Early Continuous Positive Airway Pressure: A Randomized, Controlled TrialPediatrics, 2009
- Neonatal nasal intermittent positive pressure ventilation: a survey of practice in EnglandArchives of Disease in Childhood - Fetal and Neonatal Edition, 2007
- Implementation of surfactant treatment during continuous positive airway pressureJournal of Perinatology, 2007
- Nasal Intermittent Mandatory Ventilation Versus Nasal Continuous Positive Airway Pressure for Respiratory Distress Syndrome: A Randomized, Controlled, Prospective StudyThe Journal of Pediatrics, 2007
- Nasal CPAP has become an indispensable part of the primary treatment of newborns with respiratory distress syndromeActa Paediatrica, 2007
- Newer experience with CPAPSeminars in Neonatology, 2002
- Nasal continuous positive airway pressure and outcomes of preterm infantsJournal of Paediatrics and Child Health, 2001